RT Journal Article
T1 Effect on an Oral Nutritional Supplement with beta-Hydroxy-beta-methylbutyrate and Vitamin D on Morphofunctional Aspects, Body Composition, and Phase Angle in Malnourished Patients
A1 Cornejo-Pareja, Isabel
A1 Ramirez, Maria
A1 Camprubi-Robles, Maria
A1 Rueda, Ricardo
A1 Vegas-Aguilar, Isabel Maria
A1 Garcia-Almeida, Jose Manuel
K1 malnutrition
K1 muscle loss
K1 oral nutritional supplements
K1 cancer
K1 beta-hydroxy-beta-methylbutyrate
K1 phase angle
K1 body cell mass
K1 Cancer-patients
K1 Muscle mass
K1 Malnutrition
K1 Cachexia
K1 Support
K1 Chemotherapy
K1 Sarcopenia
K1 Outcomes
K1 Risk
K1 Association
AB This is a retrospective study of data from clinical practice to observe the effect of a high-calorie, high-protein oral nutritional supplement (ONS) with beta-hydroxy-beta-methylbutyrate (HMB) on nutritional status, body weight, and muscle-related parameters in 283 adult patients with or at risk of malnutrition under standard of care, 63% being cancer patients. They were recommended to increase physical activity and energy and protein intake from regular diet plus two servings per day of a specialized ONS enriched with HMB or standard ONS for up to 6 months. Dietary records, adherence and tolerance to ONS, nutritional status, body composition, handgrip strength, and blood analysis at the beginning and the end of the intervention were recorded. This program improved nutritional status from 100% malnourished or at risk of malnutrition at baseline to 80% well-nourished at final visit. It also increased body weight by 3.6-3.8 kg, fat-free mass by 0.9 to 1.3 kg, and handgrip strength by 4.7 to 6.2 kg. In a subgroup of patients (n = 43), phase angle (PhA), and body cell mass (BCM) increased only in the patients receiving the ONS enriched with HMB (0.95 (0.13) vs. -0.36 (0.4), and 2.98 (0.5) vs. -0.6 (1.5) kg, mean difference (SE) from baseline for PhA and BCM, respectively), suggesting the potential efficacy of this supplement on muscle health.
PB Mdpi
YR 2021
FD 2021-12-01
LK https://hdl.handle.net/10668/26981
UL https://hdl.handle.net/10668/26981
LA en
DS RISalud
RD Apr 7, 2025